Furthermore, a study by Jeong et al. reported that the combination of EZN-2208 with bevacizumab was clinically acceptable (prolonged disease stabilization in two patients) and resulted in reduced HIF-1α protein levels in tumor biopsy samples from five out of seven patients [222]. Here, HIF1A is linked to neoplasm.